Charles River Laboratories Completes Acquisition of Rockville’s Vigene Biosciences

Vigene Biosciences Expansion 245 New Jobs
Published on :

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on future performance.

Charles River Laboratories to Acquire Rockville’s Vigene Biosciences to Enhance Gene Therapy Capabilities

Published on :

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.